Nearly two years after the U.S. Food and Drug Administration (FDA) ordered MJFF research partner 23andMe to stop marketing its direct-to-consumer genetic test for health reports, the DNA testing company has launched its rebranded Personal Genome Service.
“We’ve worked with the FDA for nearly two years to establish a regulatory path for direct-to-consumer genetic testing. We are a better company with a better product as a result of our work with the FDA,” said 23andMe co-founder and CEO Anne Wojcicki in a press release. “This is an incredibly dynamic time in genetics and we’re excited to be at the leading edge of bringing genetics directly to individuals as they begin to learn about their 23 pairs of chromosomes.”
The genome is a person’s full set of DNA: the genetic information that accounts for who we are, from hair color to disease risk. The 23andMe Personal Genome Service analyzes the genome for insights into one’s health, ancestry, wellness and personal traits, and the site produces reports on each. The cost is $199, and users can contribute their genetic data to research if they choose.
Genetic Information Fuels Parkinson’s Research
In addition to its consumer service, 23andMe is a big name in research, including Parkinson’s disease (PD) research. The Michael J. Fox Foundation partners with the company toward greater understanding of PD genetics and progression through its Parkinson’s research initiative.
People with Parkinson’s send in a saliva sample and complete online surveys about their history and experience with the disease to provide data toward greater understanding of PD. Participants also can access the 23andMe Personal Genome Service at no cost.
Learn more about results from the 23andMe Parkinson's research initiative and how you can get involved.